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The defensive skin secretions of many amphibians are a rich source of bradykinins and bradykinin-related peptides (BRPs).
Members of this peptide group are also common components of reptile and arthropod venoms due to their multiple biological
functions that include induction of pain, effects on many smooth muscle types, and lowering systemic blood pressure.
While most BRPs are bradykinin receptor agonists, some have curiously been found to be exquisite antagonists, such as the
maximakinin gene-related peptide, kinestatin—a specific bradykinin B
2
-receptor antagonist from the skin of the giant fire-bellied
toad, Bombina maxima. Here, we describe the identification, structural and functional characterization of a heptadecapeptide
(DYTIRTRLHQGLSRKIV), named ranakinestatin-PPF, from the skin of the Chinese ranid frog, Pelophylax plancyi fukienensis,
representing a prototype of a novel class of bradykinin B
2
-receptor specific antagonist. Using a preconstricted preparation of rat
tail arterial smooth muscle, a single dose of 10−6M of the peptide effectively inhibited the dose-dependent relaxation effect of
bradykinin between 10−11Mand 10−5Mand subsequently, this effectwas pharmacologically-characterized using specific bradykinin
B
1
- (desArg-HOE140) and B
2
-receptor (HOE140) antagonists; the data from which demonstrated that the antagonism of the novel
peptide was mediated through B
2
-receptors. Ranakinestatin—PPF—thus represents a prototype of an amphibian skin peptide
family that functions as a bradykinin B
2
-receptor antagonist herein demonstrated using mammalian vascular smooth muscle.
1. Introduction
Bradykinin (BK) is a nonapeptide with the primary struc-
ture, RPPGFSPFR. It is a peptide with a wide spectrum of
biological effects that have been most extensively studied in
mammals [1, 2]. A major physiological role for the peptide
in mammals, including humans, is in the maintenance of
systemic blood pressure through its role in dilation of
arterial smooth muscle that effectively counteracts the con-
strictor effects of angiotensin-II [3–5]. This vasoregulatory
role has been exploited clinically through the introduction
of inhibitors to the angiotensin-II generating/bradykinin-
degrading protease, angiotensin-converting enzyme (ACE),
that still represent the front-line therapeutics for the treat-
ment of hypertension [6, 7]. Of major interest to the peptide
chemist/biologist is that the lead compounds for the design
of ACE inhibitors—a milestone in twentieth century drug
discovery—was a family of so-called bradykinin-potentiating
peptides (BPPs) from the venom of the South American pit
viper, Bothrops jararaca [8]. Such BPPs are now known to be
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of widespread occurrence in snake venoms and analogs have
recently been reported from the defensive skin secretions of
phyllomedusine frogs [9].
Bradykinins and related peptides (BRPs) are known to
be widespread and abundant components of many venoms
and defensive secretions and are particularly diverse in
structure within the skin secretions of amphibians [10, 11].
This widespread occurrence across taxa is not surprising in
view of their wide spectrum of biological effects, not the least
of which are their potent algesic effects [10, 11].
Amphibian skin BRPs appear to reflect the primary
structures of their endogenous counterparts in vertebrate
predator taxa as analogs to most of these amphibian BRPs
have been found to be generated from respective plasma
proteins by appropriate chemical or physical treatments [10,
11].
While most amphibian BRPs have agonist properties
following interaction with appropriate taxon-specific recep-
tors in sourced tissues, some of these, and indeed other
structurally unrelated peptides, have been found to have
mammalian BK receptor antagonist properties [10, 11]. The
skin secretions from bombinid toads appear to be a rich
source of receptor agonist BRPs but also of these structurally
diverse and structurally unrelated BK receptor antagonist
peptides [12–17]. The skin secretions of ranid frogs, however,
have proven to be the richest amphibian source of BRPs
[10, 18] yet, to date, they remain poorly evaluated for the
presence of BK receptor antagonists.
Here, we describe the identification of a bradykinin
inhibitory heptadecapeptide, named ranakinestatin-PPF, in
the skin secretion of a ranid frog, the Fukien gold-striped
pond frog, Pelophylax plancyi fukienensis. The peptide was
first isolated through its inhibitory effects on bradykinin-
induced dilation of a rat tail artery smooth muscle prepara-
tion andwas subsequently subjected to preliminary structural
characterization using MS/MS fragmentation sequencing.
Using this sequence data to design a degenerate PCR primer,
the cDNA encoding its biosynthetic precursor was success-
fully cloned from a skin secretion-derived cDNA library,
translation ofwhich established the peptides unequivocal pri-
mary structure. Pharmacological characterization of a syn-
thetic replicate of the peptide, using the rat tail artery smooth
muscle preparation, confirmed its functional bradykinin
inhibitory effects and established its probable molecular
target as the bradykinin B
2
-receptor. Ranakinestatin-PPF
thus represents the prototype of a novel family of bradykinin
B
2
-receptor antagonists from the skin secretions of ranid
frogs.
2. Materials and Methods
2.1. Specimen Biodata and Secretion Harvesting. Adult spec-
imens of the Fukien gold-striped pond frog, Pelophylax
plancyi fukienensis (𝑛 = 3, snout-to-vent length 7 cm),
were captured in paddy fields around Fuzhou City, Fujian
Province, People’s Republic of China (Fukien is the ancient
Chinese name for Fujian). Secretion harvesting was per-
formed in the field after which the frogs were released
unharmed. Skin secretion was obtained from the dorsal skin
using gentle transdermal electrical stimulation as previously
described [19]. The stimulated secretions were washed from
the skin using deionized water and divided into either 0.2%
(v/v) aqueous trifluoroacetic acid (for subsequent peptide
characterization) or into cell lysis/mRNA stabilization buffer
(Dynal) for subsequent cDNA library construction. Sampling
of skin secretion was performed by MZ under a UK Animal
(Scientific Procedures) Act 1986, project licence issued by
the Department of Health, Social Services and Public Safety,
Northern Ireland, and subsequent pharmacological experi-
ments using rat tissueswere performed byMZunder a similar
personal licence issued by the same authority. All procedures
on animals had additionally been vetted by the IACUC of
Queen’s University Belfast and approved.
2.2. Reverse Phase-HPLC Fractionation of Skin Secretion. The
acidified skin secretion washings were clarified of micropar-
ticulates by centrifugation (13,000×g for 10min) and the
decanted clear supernatant was subjected to reverse-phase
HPLC fractionation using a Thermoquest gradient HPLC
system fitted with a Jupiter semipreparative C-18 column
(1 × 25 cm). This was eluted with a linear gradient formed
from 0.05 : 99.95 (v/v) trifluoroacetic acid (TFA)/water to
0.05 : 19.95 : 80.00 (v/v/v) TFA/water/acetonitrile in 240min
at a flow rate of 1mL/min. Fractions (1mL) were collected
at minute intervals and the effluent absorbance was continu-
ously monitored at 𝜆214 nm. Samples (100𝜇L) were removed
from each fraction in triplicate and lyophilized and stored at
−20∘C prior to smooth muscle pharmacological analysis.
2.3. Bioactivity Screening Using Arterial Smooth Muscle.
Female albino Wistar rats (200–250 g) were euthanized by
asphyxiation followed by cervical dislocation. The tail skin
was removed and the major tail artery was identified and
moistened with Krebs’ solution (118mM NaCl, 4.7mM KCl,
25mM NaHCO
3
, 1.15mM NaH
2
PO
4
, 2.5mM CaCl
2
, 1.1mM
MgCl
2
, and 5.6mM glucose) prior to dissection of the
proximal region that then placed in ice-cold Kreb’s solution.
Two mm wide rings of this tissue were cut and mounted
onto a transducer prior to placing in 2mL organ baths
containing Kreb’s solution (37∘C) flowing at 2mL/min with
constant gentle bubbling of 95% O
2
/5% CO
2
. These rings of
muscle were equilibrated for 1 h before experimental proce-
dures were initiated. Preparations were perfused constantly
with 1 × 10−5M phenylephrine in Kreb’s solution in order
to obtain constriction plateaux and following this, relative
relaxation events were recorded following applications of
reconstituted 100 𝜇L samples fromHPLC fractions (#1–#240)
of Pelophylax plancyi fukienensis skin secretion. This was
carried out to exclude those fractions (25) containing direct
arterial smooth muscle relaxant activity. Following this, the
remaining fractions (215) were employed in the follow-
ing procedure for identification of bradykinin inhibitory
peptides. The preparations were incubated as before, with
phenylephrine (1 × 10−5M) until constriction plateaux were
obtained. Following this, combinations of phenylephrine (1 ×
10−5M) and reconstituted nonmyoactive fractions were
The Scientific World Journal 3
applied to individual preparations and incubated for 20min.
After this period, a single dose of bradykinin (1 × 10−6M)was
added to the medium in each organ bath. Changes in arterial
smooth muscle tone were measured by a pressure transducer
system and the relaxations induced by bradykinin in the
presence of reconstituted fractions were calculated using the
PowerLab computer package.
2.4. Structural Characterization of the Bradykinin Inhibitory
Peptide. Reverse phase HPLC fraction #100 was found to
possess bradykinin inhibitory activity in the arterial smooth
muscle preparation and a sample of this fraction was sub-
jected to tandemMS/MS fragmentation sequencing using an
LCQ-Fleet electrospray ion-trapmass spectrometer (Thermo
Fisher, San Jose, CA, USA).
2.5. Molecular Cloning of the Bradykinin Inhibitory Pep-
tide Biosynthetic Precursor-Encoding cDN. Polyadenylated
mRNA was isolated from the stabilization buffer/skin secre-
tion mixture using magnetic oligo-dT beads as described by
the manufacturer (Dynal Biotech, UK) and it was reverse
transcribed. The isolated mRNA was then subjected to 5󸀠-
and 3󸀠-rapid amplification of cDNA ends (RACE) procedures
to obtain full-length bradykinin inhibitory peptide precursor
nucleic acid sequence data using a SMART-RACE kit (Clon-
tech UK) as per manufacturer’s instructions. Briefly, the 3󸀠-
RACE reactions employed a nested universal (NUP) primer
(supplied with the kit) and a degenerate sense primer (S: 5󸀠-
GAYTAYACIHTIMGIACIMGIHT-3󸀠) (Y = C/T, I = deoxyi-
nosine, H = A/T/C, M = A/C) that was complementary to
the N-terminal amino acid sequence, D-Y-T-I/L-R-T-R-L/I-,
of the bradykinin inhibitory peptide. The 3󸀠-RACE reactions
were purified and cloned using a pGEM-T vector system
(Promega Corporation) and sequenced using an ABI 3100
automatedDNA sequencer.The sequence data obtained from
the 3󸀠-RACEproductswere used to design a specific antisense
primer (AS: 5󸀠-CCACATCAGATGACTTCCAAATGAT-3󸀠)
to a defined conserved site within the 3󸀠 nontranslated region
of the bradykinin inhibitory peptide-encoding transcripts. 5󸀠-
RACE was carried out using this primer in conjunction with
theNUPprimer and resultant products were purified, cloned,
and sequenced.
2.6. Chemical Synthesis of the Bradykinin Inhibitory Peptide.
Once the unequivocal primary structure of the bradykinin
inhibitory peptide had been established through a combi-
nation of MS/MS fragmentation sequencing and translation
from cloned precursor-encoding cDNA, a synthetic replicate
was produced using solid-phase Fmoc chemistry on a PS3
automated solid-phase synthesizer (Protein Technologies,
Inc., AZ, USA). The authenticity of the peptide structure was
confirmed by MS/MS fragmentation sequencing following
reverse phase HPLC purification of cleaved and deprotected
synthesis mixture.
2.7. Pharmacological Characterization of Synthetic Bradykinin
Inhibitory Peptide Using Rat Tail Artery Smooth Muscle. Rat
tail artery smooth muscle preparations were prepared for
experimental procedures as previously described. Two series
of experiments were performed to address the quantitative
pharmacological characterisation of the novel bradykinin
inhibitory peptide.
(1) The inhibitory effect of the peptide at a single pre-
treatment concentration of 10−6M was assessed on
the dose-dependent relaxation of the artery smooth
muscle preparations induced by bradykinin in the
concentration range of 10−11–10−5M.
(2) The effects of pretreatment of artery smooth muscle
preparations with the specific bradykinin B
1
receptor
antagonist (desArg HOE 140) or the bradykinin B
2
receptor antagonist (HOE 140) (Sigma-Aldrich, UK)
were assessed to compare with those obtained with
the bradykinin inhibitory peptide.
Firstly, the stabilized preparations were exposed to
bradykinin in the concentration range of 10−11–10−5M with
and without pretreatment with the bradykinin inhibitory
peptide at a single dose of 1 × 10−6M. For these exper-
iments, the bradykinin inhibitory peptide was added to
the organ bath once a stable plateau of phenylephrine-
induced constriction had been obtained and after a period
of 10min, bradykinin dose-response curves (10−11–10−5M)
were constructed.
In a second series of experiments, the specific bradykinin
receptor antagonists were employed likewise at a single dose
(3 × 10−7M) prior to the procedure described above.
During all of these experiments, changes in tension of
the arterial smooth muscle preparation were detected by
pressure transducers connected to a PowerLab System (AD
Instruments Pty Ltd.). Data from six consecutive experiments
with each treatment were analyzed to obtain the mean
and standard error of responses by Student’s 𝑡-test using
the Graph Pad Prism program and dose-response curves
were constructed using a best-fit algorithm through the data
analysis package provided. Responses were plotted as tension
changes in grams against final molar concentrations of the
bradykinin inhibitory peptide present in the organ baths.
3. Results
3.1. Reverse Phase HPLC Fractionation of Skin Secretion and
Preliminary Bradykinin InhibitoryActivity Screening. Reverse
phase HPLC fractionation of P. plancyi fukienensis skin
secretions resulted in the resolution of many components
indicating a high degree of molecular complexity. Prelim-
inary screening of samples of each fraction using rat tail
artery smooth muscle identified 25 fractions that contained
direct vasorelaxant activity and these were excluded from the
next series of bioassays that sought fractions with bradykinin
inhibitory activity. These fractions were those that could
effectively reduce the vasorelaxant action of a single dose
(10−6M) of bradykinin. Fraction #100 was found to be
effective in this respect and the appropriate region of the
reverse phase HPLC chromatogram of skin secretion in
which this peptide eluted is shown in Figure 1.
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Figure 1: Region of reverse phase HPLC chromatogram of Pelo-
phylax plancyi fukienensis skin secretion indicating elution posi-
tion/retention time of the peak of absorbance corresponding to
bradykinin inhibitory activity (arrow).
3.2. Structural Characterization of the Bradykinin Inhibitory
Peptide. A sample of skin secretion reverse phase HPLC
fraction #100was removed and subjected toMS analysis using
the electrospray ion-trap mass spectrometer. The sample was
found to contain a single major peptide of mass 2056.4Da,
deduced from its doubly charged ion (Figure 2(a)). MS/MS
fragmentation sequencing of this doubly charged ion (M +
2H)2+, m/z 1029.3 (Figure 2(b)), produced the following
sequence: DYTL/IRTRL/IHQGL/ISRKL/IV (Figure 2(c)).
3.3. Molecular Cloning of the Bradykinin Inhibitory Pep-
tide Biosynthetic Precursor-Encoding cDNA and Bioinformatic
Analyses. Themolecular cloning strategy adopted for design-
ing a degenerate primer pool to the N-terminal 8 residues of
the bradykinin inhibitory peptide for use in 3󸀠-RACE PCR
proved to be successful. A single transcript was consistently
obtained and was of identical nucleotide sequence in at
least 25 different clones. The nucleotide and translated open-
reading frame amino acid sequence of this is shown in
Figure 3. The open-reading frame encoding the bradykinin
inhibitory peptide precursor consisted of 61 amino acid
residues with a domain architecture that was consistent with
that observed for the majority of amphibian skin peptide
precursors. The first domain was constituted by a putative
22-residue signal peptide followed by a 20-residue acidic
spacer peptide that immediately preceded a classical-KR-
propeptide convertase processing site upstream of a mature
peptide encoding domain (Figure 4). From this translated
cloned cDNA template, the unequivocal primary structure
of the mature bradykinin inhibitory peptide was established
as DYTIRTRLHQGLSRKIV (2056.38Da). The C-terminal
residues of the mature peptide domain (and precursor)
were IV, indicating that the mature peptide was not C-
terminally amidated.The peptide was named ranakinestatin-
PPF in accordance with previously established nomenclature.
Kinestatinwas a prototype bradykinin B
2
-receptor antagonist
peptide from amphibian skin, that of the bombinid toad,
Bombina maxima [15], hence, the adoption of this functional
name with the addition of the prefix, Rana. The suffix,
-PPF, is an abbreviation of the species (and subspecies)
of origin, Pelophylax Plancyi Fukienensis. This provides the
basis for the future systematic classification of additional
homologs from other species. Bioinformatic analysis of the
ranakinestatin-PPF precursor using the US National Center
for Biotechnological Information (NCBI) online database
and the BLAST program found two archived homologs. The
three domains of these homologs are aligned with those of
the ranakinestatin-PPF precursor domains in Figures 4(a)–
4(c).These ranakinestatin-PPFhomologs are both from ranid
frogs, the antimicrobial peptide mantzorumin-B
1
, from the
skin of Amolops mantzorum (accession no. ADM34242) and
the antinociceptive peptide odorranaopin, from the brain of
Odorrana grahami (ADP37000) [20]. Also included in this
comparison are the biosynthetic precursor domain sequences
of ranakinestatin-OS (Odorrana schmackeri), deduced from
cloned skin secretion-derived cDNA (unpublished data). Of
particular interest, illustrated in Figure 4(d), is the presence
of a sequence identical to the fully conserved N-terminal
nonapeptide of the ranakinestatins, within the N-terminal
domain of the Bombina maxima skin kininogen-2 precursor,
that also encodes maximakinin and kinestatin [15].
3.4. Pharmacological Characterization of Synthetic
Ranakinestatin-PPF Peptide Using Rat Tail Artery Smooth
Muscle. The chemical synthesis of ranakinestatin-PPF
was both successful and straightforward resulting in a
product of >95% purity (data not shown). The effect on
the dose-dependency of bradykinin-induced relaxation of
phenylephrine preconstricted rat tail artery smooth muscle
was assessed following the pretreatment of preparations
with a single dose (10−6M) of synthetic ranakinestatin-PPF.
There was a significant reduction in bradykinin-induced
vasorelaxation at all concentrations between 10−11M and
10−5M (Figure 5(a)) (𝑃 < 0.05 at BK concentrations of
10−11 and 10−10M; 𝑃 < 0.001 at BK concentrations between
10−9M and 10−5M). The effects of ranakinestatin-PPF at a
single dose of 10−6M and the specific bradykinin B
2
- and
B
1
-receptor antagonists, HOE 140, and desArg-HOE 140, at
single doses of 3 × 10−7M, respectively, on the vasorelaxation
induced by a single dose of 10−6M bradykinin blockade
on rat tail artery preparations were assessed. The results
(Figure 5(b)) demonstrated that the target BK receptor for
the inhibitory actions of ranakinestatin-PPF was likely to
be of the B
2
-subtype. The B
2
-receptor antagonist, HOE 140,
caused a significant reduction (𝑃 < 0.05) in the vasorelaxant
effects of bradykinin in this preparation with the B
1
-receptor
antagonist, desArg-HOE 140, producing no significant effect.
Ranakinestatin-PPF caused the most significant observed
reduction in bradykinin-induced vasorelaxation (𝑃 < 0.001).
4. Discussion
Bradykinin-related peptides (BRPs) are significant compo-
nents of the defensive skin secretions of many amphibians,
most notably those of ranid and phyllomedusine frogs and
bombinid toads [9–15, 17, 18, 20]. One of the reasons for
their widespread occurrence and relative abundance is most
likely due to their possession of a plethora of biological effects
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Figure 2: (a) Electrospray MS spectrum of a sample from reverse phase HPLC fraction #100 that contained bradykinin inhibitory activity.
The doubly charged ion (m/z 1029.30), triply charged ion (m/z 686.99), and quadruply charged ion (m/z 515.59) of a peptide with a parent
mass of 2056.4Da were detected. (b) MS/MS fragmentation spectrum of the doubly charged ion at m/z 1029.30. (c) Theoretical singly and
doubly charged b- and y-ion series arising fromMS/MS fragmentation of the bradykinin inhibitory peptide with observed ions indicated in
bold typeface and underlined.
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M  F  T   L  K  K  S   L  L  L   L  F  F   L  G  I  V 
1 ATGTTCACGT TGAAGAAATC CCTGTTGCTC CTTTTCTTTC TTGGGATCGT 
TACAAGTGCA ACTTCTTTAG GGACAACGAG GAAAAGAAAG AACCCTAGCA 
S  L  S   L  C  E   E  E  R  D   A  D  E   E  E  N  
51 CTCCTTATCT CTCTGTGAAG AAGAGAGAGA TGCCGACGAA GAGGAAAATG 
GAGGAATAGA GAGACACTTC TTCTCTCTCT ACGGCTGCTT CTCCTTTTAC 
G  E  E  V   T  K  K   E  V  K   R  D  Y  T   I  R  T 
101 GGGAGGAAGT TACAAAGAAA GAAGTAAAAA GAGATTACAC CATTAGAACC 
CCCTCCTTCA ATGTTTCTTT CTTCATTTTT CTCTAATGTG GTAATCTTGG 
R  L  H   Q  G  L  S   R  K  I   V
151 AGGCTTCACC AGGGATTATC AAGGAAAATT GTGTGAATAT TTTAAAAAAA 
TCCGAAGTGG TCCCTAATAG TTCCTTTTAA CACACTTATA AAATTTTTTT 
201 CATCAAAACA TCATTTGGAA GTCATCTGAT GTGGAATATC ATTTAGCTAA 
GTAGTTTTGT AGTAAACCTT CAGTAGACTA CACCTTATAG TAAATCGATT 
251 ATCCTAAATG TCTGACAAAA AATAATGATA TCACATCACG CAAAAAAAAA 
TAGGATTTAC AGACTGTTTT TTATTACTAT AGTGTAGTGC GTTTTTTTTT 
301 AAAAAAAAAA AAAAAAAAAA 
TTTTTTTTTT TTTTTTTTTT 
∗
Figure 3: Nucleotide and translated open-reading frame amino acid sequence of cloned Pelophylax plancyi fukienensis skin secretion-derived
cDNA encoding the biosynthetic precursor of the bradykinin inhibitory peptide, named ranakinestatin-PPF. The putative signal peptide id
double-underlined, the mature peptide is single-underlined and the stop codon is indicated with an asterisk.
Pelophylax plancyi fukienensis signal peptide MFTLKKSLLLLFFLGIVSLSLC
Amolops mantzorum  signal peptide MFTLKKPLLLLFFLGTVSLSLC
Odorrana grahami signal peptide MFTLKKPLLLIFFLGTISLSLC
Odorrana schmackeri signal peptide              MFTTKKSMLLLFFLGTISLSLC 
∗ ∗∗ ∗ ∗∗
(a)
Pelophylax plancyi fukienensis acidic spacer peptide EEERDADEEENGEEVTKKEV 
Amolops mantzorum acidic spacer peptide EQERDADEEENGGEVTEEEV 
Odorrana grahami acidic spacer peptide EQERDADEEENGGEVTEKEV 
Odorrana schmackeri acidic spacer peptide EQERDADEEENGGEVTEKEV 
KR
KR 
KR 
KR 
∗ ∗ ∗∗
(b)
Pelophylax plancyi fukienensis mature peptide (ranakinestatin-PPF) DYTIRTRLHQGLSRKIV
Amolops mantzorum mature peptide (ranakinestatin-AM) DYTIRTRLHQELSRKVL
Odorrana grahami mature peptide (ranakinestatin-OG) DYTIRTRLHQESSRKVL
Odorrana schmackeri  mature peptide (ranakinestatin-OS)               DYTIRTRLHQGLSRKIV 
∗∗ ∗∗
(c)
Bombina maxima kininogen-2 
MRLWFCLSFFIVLCLEHFPGTLADERNNRDYTIRTRLHGHHKPSRNNRYAIKTSIHGHHIPRNVPESEEKTEQFLRDLPKINRKGPRPPGFSPFRGKFHSQSLRQIPGLGPLRG 
(1) Ranakinestatin residues 1-9. (2) Maximakinin (syn. bombinakinin M). (3) Kinestatin.
(1) (2) (3)
(d)
Figure 4: Bioinformatic analysis of the ranakinestatin-PPF biosynthetic precursor with homologs reported from other amphibian sources.
Accession numbers for cited sequences arePelophylax plancyi fukienensis ranakinestatin-PPF (HG518554),Amolopsmantzorum antimicrobial
peptidemantzorumin-B
1
(ADM34242),Odorrana grahami odorranaopin (ADP37000),Odorrana schmackeri ranakinestatin-OS (HG518555),
and Bombina maxima skin kininogen-2 (P83055). (a) Comparison of putative N-terminal signal peptide domains of respective biosynthetic
precursors. Sites of amino acid differences are indicated with asterisks (6/22). (b) Comparison of acid spacer peptide domains of respective
biosynthetic precursors. Sites of amino acid differences are indicated with asterisks (4/20). Note that this domain terminates in the conserved
basic amino acid residue doublet (-KR-) (indicated in italics and underlined) that represents the site of propeptide convertase cleavage
generating the mature peptide. (c) Comparison of mature (ranakinestatin) peptide domains of respective biosynthetic precursors. Sites of
amino acid differences are indicated with asterisks (4/17). (d) The full-length sequence of Bombina maxima skin kininogen-2 indicating
domains containing (1) the fully conserved ranakinestatin residues 1–9, (2) the bradykinin receptor agonist peptide, maximakinin (syn.
bombinakinin M), and (3) the bradykinin B
2
-receptor antagonist peptide, kinestatin.
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Figure 5: (a) Bradykinin dose-response curves using rat arterial smooth muscle in the absence (◼) and presence (e) of ranakinestatin-PPF
(generic nameQUB2056) at a single dose of 10−6M. (b) Relaxation effect of bradykinin on rat arterial smoothmuscle at a single dose of 10−6M
and the effect of pretreatment with ranakinestatin-PPF (QUB 2056) at 10−6M (𝑃 < 0.001), the bradykinin B
2
-receptor antagonist, HOE140
(3 × 10−7M) (𝑃 < 0.05), and the bradykinin-B
1
-antagonist, desArg-HOE-140 (3 × 10−7M) (NS—not significant). All data points represent
the mean ± SEM of seven applications.
including those on the cardiovascular, gastrointestinal, and
innate immune systems and in nociception [10, 11].
As vertebrate bradykinins are one of the few families
of endogenous regulatory peptides that are taxon specific
with respect to structural/functional attributes, it is not
surprising that the spectrum of BRPs present in amphibian
skin defensive secretions should reflect the spectrum of
endogenous homologs present in their vertebrate predators
[10, 11]. However, while most research has been focused
on the identification of amphibian skin-derived bradykinin
receptor agonists that could cause pharmacological overloads
of respective predator kinin-regulated systems, there is no
particular reason why natural selection should necessarily
favour the evolution of agonists over antagonists. Indeed, the
peptide, kinestatin, from the skin secretion of the giant fire-
bellied toad, Bombinamaxima, was found to be an antagonist
of high potency onmammalian bradykinin B
2
-receptors [15].
Here, we report the prototype of another structural class
of bradykinin B
2
-receptor antagonist from the skin secretion
of a Chinese ranid frog, Pelophylax plancyi fukienensis, which
was named in accordance as ranakinestatin-PPF. This pep-
tide, unlike kinestatin, does not display any primary struc-
tural similarity to canonical bradykinin. Peptides exhibiting
high degrees of identity with ranakinestatin-PPF have been
previously reported from either the skin or brain tissues of
the ranid frogs, Amolops mantzorum and Odorrana grahami,
respectively [20]. However, the Amolops mantzorum skin
peptide, which was named, mantzorumin-B
1
, was believed
to be an antimicrobial peptide. However, the details con-
tained under its accession number, ADM34242, indicate
that the data remains unpublished and that the peptide was
predicted from translated cloned precursor-encoding cDNA
rather than being isolated and biologically characterized.The
peptide thus has not, according to the current literature,
been evaluated for antimicrobial activity and the probability
is that it was named as such due to the similarity of the
signal peptide and acidic spacer peptide regions of the
biosynthetic precursor, with corresponding domains in the
precursors of antimicrobial peptides. This, however, is a
highly unreliable characteristic throughwhich to functionally
name mature amphibian skin peptides without recourse to
biological evaluation. Ranakinestatin-PPF was found to be
devoid of any antimicrobial activity at concentrations upto
and including 250 𝜇M (2.5 × 10−4M) (data not shown).
The peptide from the brain of Odorrana grahami was
curiously named, odorranaopin, due to its antinociceptive
activity despite lacking any degree of structural identity with
any established opiate receptor ligand [20]. As the peptidewas
found to inhibit bradykinin-induced contraction of ileum
smooth muscle and the fact that bradykinin is a potent noci-
ceptive agent, it could be concluded that the antinociceptive
effects of odorranaopin were mediated through its action as
a bradykinin receptor antagonist rather than through any
interaction with opiate receptor pathways [11, 20]. Indeed,
in the present study, using rat tail arterial smooth muscle,
the analog of this peptide, here more appropriately named,
ranakinestatin-PPF, was found to inhibit bradykinin induced
relaxation known to be mediated through the B
2
-receptor
subtype [15].
Odorranaopin was predicted from a cDNA that was
cloned froma brain-derived library of the frog,Odorrana gra-
hami [20]. Curiously in this report, the frogs were euthanized
using a technique that was very similar to that used to induce
and acquire defensive skin secretions in previous reports
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[21]. Bearing in mind that both skin secretion peptides and
their precursor-encoding cDNAs are present in such skin
secretions [20, 21], it would be most difficult to acquire brain
tissues from cadavers without contaminating such from this
source. Thus, the possibility of a skin origin of this material
was tested using skin secretion from a closely related species
of frog, Odorrana schmackeri. Figures 4(a)–4(c) show that
the cDNA encoding the peptide precursor was successfully
cloned from this source indicating that in theOdorrana genus
this is a defensive skin secretion peptide.
In view of the inconsistencies of nomenclature, we pro-
pose the name for this family of ranid frog skin bradykinin
B
2
-receptor antagonists as ranakinestatins, with a suffix
appended to indicate the species of origin (see Figure 4(c)).
Interrogation of online protein databases with the primary
structure of ranakinestatin-PPF, in addition to revealing
the two previously mentioned ranid frog homologs, also
located a nine-amino acid residue sequence corresponding
to the N-terminal fully conserved nonapeptide of ranakines-
tatins, within an N-terminally located domain of the skin
kininogen-2 precursor from the bombinid toad, Bombina
maxima [15] (Figure 4(d)). Of special note is that this skin
kininogen also encodes single copies of the bradykinin B
2
-
receptor agonist, maximakinin (syn. bombinakinin M) [14]
and the bradykinin B
2
-receptor antagonist, kinestatin [15].
The complete conservation of the N-terminal nonapeptide
sequence of the ranakinestatins and its occurrence within
skin kininogen-2 of a bombinid toad would suggest that this
represents the active core of the peptide and structure/activity
studies to address this question are underway at present.
Data Deposition
The nucleotide sequences of cloned cDNAs encoding
the biosynthetic precursors of ranakinestatin-PPF and
ranakinestatin-OS, from the skin secretions of Pelophylax
plancyi fukienensis and Odorrana schmackeri, respectively,
have been deposited in the EMBL Nucleotide Sequence
Database under the accession codes HG518554 and
HG518555.
Conflict of Interests
The authors declare that they have no conflict of interests.
Authors’ Contribution
Jie Ma and Yu Luo contributed equally to this work.
References
[1] K. D. Bhoola, C. D. Figueroa, and K. Worthy, “Bioregulation of
kinins: kallikreins, kininogens, and kininases,” Pharmacological
Reviews, vol. 44, no. 1, pp. 1–80, 1992.
[2] D. Regoli and J. Barabe´, “Pharmacology of bradykinin and
related kinins,” Pharmacological Reviews, vol. 32, no. 1, pp. 1–46,
1980.
[3] A. Benetos, B. I. Levy, P. Lacolley, F. Taillard, M. Duriez, andM.
E. Safar, “Role of angiotensin II and bradykinin on aortic colla-
gen following converting enzyme inhibition in spontaneously
hypertensive rats,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 17, no. 11, pp. 3196–3201, 1997.
[4] L. J. Heller and D. E. Mohrman, “Comparison of blood pres-
sure responses to intra-arterial and intra-venous injections of
angiotensin I, angiotensin II and bradykinin,” Life Sciences, vol.
62, no. 9, pp. PL121–PL125, 1998.
[5] C. Labinjoh, D. E. Newby, P. Dawson et al., “Fibrinolytic actions
of intra-arterial angiotensin II and bradykinin in vivo in man,”
Cardiovascular Research, vol. 47, no. 4, pp. 707–714, 2000.
[6] D. B. Matchar, D. C. McCrory, L. A. Orlando et al., “Systematic
review: comparative effectiveness of angiotensin-converting
enzyme inhibitors and angiotensin II receptor blockers for
treating essential hypertension,” Annals of Internal Medicine,
vol. 148, no. 1, pp. 16–29, 2008.
[7] J. N. Sharma, “Hypertension and the bradykinin system,”
Current Hypertension Reports, vol. 11, no. 3, pp. 178–181, 2009.
[8] M. A. F. Hayashi and A. C. M. Camargo, “The Bradykinin-
potentiating peptides from venom gland and brain of Bothrops
jararaca contain highly site specific inhibitors of the somatic
angiotensin-converting enzyme,” Toxicon, vol. 45, no. 8, pp.
1163–1170, 2005.
[9] K. Conceic¸a˜o, K. Konno, R. L. de Melo et al., “Isolation and
characterization of a novel bradykinin potentiating peptide
(BPP) from the skin secretion ofPhyllomedusa hypochondrialis,”
Peptides, vol. 28, no. 3, pp. 515–523, 2007.
[10] J. M. Conlon, “Bradykinin and its receptors in non-mammalian
vertebrates,” Regulatory Peptides, vol. 79, no. 2-3, pp. 71–81, 1999.
[11] V. Erspamer, “Bioactive secretions of the integument,” in
Amphibian Biology, H. Heatwole and G. T. Barthalmus, Eds.,
vol. 1, pp. 179–350, The Integument, Surrey Beatty & Sons,
Chipping Norton, UK, 1994.
[12] T. Chen, D. F. Orr, A. J. Bjourson et al., “Bradykinins and
their precursor cDNAs from the skin of the fire-bellied toad
(Bombina orientalis),” Peptides, vol. 23, no. 9, pp. 1547–1555,
2002.
[13] T. Chen, D. F. Orr, A. J. Bjourson et al., “Novel bradykinins
and their precursor cDNAs from European yellow-bellied toad
(Bombina variegata) skin,” European Journal of Biochemistry,
vol. 269, no. 18, pp. 4693–4700, 2002.
[14] T. Chen, A. J. Bjourson, S. McClean et al., “Cloning of
maximakinin precursor cDNAs from Chinese toad, Bombina
maxima, venom,” Peptides, vol. 24, no. 6, pp. 853–861, 2003.
[15] T. Chen, M. O’Rourke, D. F. Orr et al., “Kinestatin: a novel
bradykinin B
2
receptor antagonist peptide from the skin
secretion of the Chinese toad, Bombina maxima,” Regulatory
Peptides, vol. 116, no. 1–3, pp. 147–154, 2003.
[16] L. Wang, Y. Chen, M. Yang et al., “Peptide DV-28 amide:
an inhibitor of bradykinin-induced arterial smooth muscle
relaxation encoded by Bombina orientalis skin kininogen-2,”
Peptides, vol. 31, no. 5, pp. 979–982, 2010.
[17] M. Yang,M. Zhou, B. Bai et al., “Peptide IC-20, encoded by skin
kininogen-1 of the European yellow-bellied toad, Bombina var-
iegata, antagonizes bradykinin-induced arterial smooth muscle
relaxation,” Journal of Pharmacy and Bioallied Sciences, vol. 3,
no. 2, pp. 221–225, 2011.
[18] Y. Sin, M. Zhou, W. Chen et al., “Skin bradykinin-related
peptides (BRPs) and their biosynthetic precursors (kininogens):
comparisons between various taxa of Chinese and North
The Scientific World Journal 9
American ranid frogs,” Peptides, vol. 29, no. 3, pp. 393–403,
2008.
[19] M. J. Tyler, D. J. M. Stone, and J. H. Bowie, “A novel method for
the release and collection of dermal, glandular secretions from
the skin of frogs,” Journal of Pharmacological and Toxicological
Methods, vol. 28, no. 4, pp. 199–200, 1992.
[20] W. Chen, X. Yang, L. Chen et al., “Gene cloning and character-
ization of novel antinociceptive peptide from the brain of the
frog, Odorrana grahami,” Biochimie, vol. 93, no. 7, pp. 1110–1114,
2011.
[21] H. Wang, X. Yan, H. Yu et al., “Isolation, characterization and
molecular cloning of new antimicrobial peptides belonging to
the brevinin-1 and temporin families from the skin ofHylarana
latouchii (Anura: Ranidae),” Biochimie, vol. 91, no. 4, pp. 540–
547, 2009.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
